GB1377308A - Pyrimidones - Google Patents

Pyrimidones

Info

Publication number
GB1377308A
GB1377308A GB774872A GB774872A GB1377308A GB 1377308 A GB1377308 A GB 1377308A GB 774872 A GB774872 A GB 774872A GB 774872 A GB774872 A GB 774872A GB 1377308 A GB1377308 A GB 1377308A
Authority
GB
United Kingdom
Prior art keywords
methyl
prepared
hydrogen
reacting
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB774872A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of GB1377308A publication Critical patent/GB1377308A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
GB774872A 1971-10-29 1972-02-18 Pyrimidones Expired GB1377308A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19400671A 1971-10-29 1971-10-29

Publications (1)

Publication Number Publication Date
GB1377308A true GB1377308A (en) 1974-12-11

Family

ID=22715935

Family Applications (2)

Application Number Title Priority Date Filing Date
GB5005373A Expired GB1377720A (en) 1971-10-29 1972-02-18 Hydroxy pyrimidines
GB774872A Expired GB1377308A (en) 1971-10-29 1972-02-18 Pyrimidones

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB5005373A Expired GB1377720A (en) 1971-10-29 1972-02-18 Hydroxy pyrimidines

Country Status (25)

Country Link
JP (2) JPS5337870B2 (fr)
AR (2) AR198798A1 (fr)
AT (2) AT321308B (fr)
AU (1) AU467600B2 (fr)
BE (1) BE790125A (fr)
CA (1) CA980778A (fr)
CH (2) CH555832A (fr)
DE (3) DE2248741C3 (fr)
DK (1) DK131465B (fr)
EG (1) EG11013A (fr)
ES (2) ES407730A1 (fr)
FI (1) FI55503C (fr)
FR (1) FR2157865B1 (fr)
GB (2) GB1377720A (fr)
IE (1) IE37043B1 (fr)
IL (2) IL40458A (fr)
LU (1) LU66304A1 (fr)
NL (1) NL166470C (fr)
NO (1) NO136574C (fr)
PH (2) PH10129A (fr)
PL (2) PL84634B1 (fr)
SE (2) SE393376B (fr)
SU (2) SU498908A3 (fr)
YU (2) YU35125B (fr)
ZA (1) ZA727362B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776870B2 (en) 2005-08-22 2010-08-17 Melior Pharmaceuticals I, Inc. Methods for modulating Lyn kinase activity and treating related disorders
US8552184B2 (en) 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
US10786503B2 (en) 2017-04-10 2020-09-29 Melior Pharmaceuticals I, Inc. Treatment of adipocytes
US12011445B2 (en) 2010-05-28 2024-06-18 Melior Pharmaceuticals I, Inc. Prevention of pancreatic cell degeneration

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55151912U (fr) * 1979-04-17 1980-11-01
JPS5752409Y2 (fr) * 1979-11-05 1982-11-15
DE3222914A1 (de) * 1982-06-18 1983-12-22 Beiersdorf Ag, 2000 Hamburg Substituierte 5-phenylthio-6-amino-pyrimidinone, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen
JPH0655686B2 (ja) * 1988-08-30 1994-07-27 宇部興産株式会社 ｐ−ブロモフェノキシアセトアルデヒドジアルキルアセタール類の製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2913462A (en) * 1959-11-17 Eahl h
GB951432A (en) * 1959-03-17 1964-03-04 Wellcome Found Pyrimidine derivatives and the manufacture thereof

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251883B2 (en) 2005-08-22 2019-04-09 Melior Pharmaceuticals I, Inc. Methods and formulations for modulating Lyn kinase activity and treating related disorders
US8343985B2 (en) 2005-08-22 2013-01-01 Melior Pharmaceuticals I, Inc. Methods for modulating Lyn kinase activity and treating related disorders
US8835448B2 (en) 2005-08-22 2014-09-16 Melior Pharmaceuticals I, Inc. Methods and formulations for modulating lyn kinase activity and treating related disorders
US9216959B2 (en) 2005-08-22 2015-12-22 Melior Pharmaceuticals I, Inc. Methods and formulations for treating cardiovascular disease
US9763945B2 (en) 2005-08-22 2017-09-19 Melior Pharmaceuticals I, Inc. Methods and formulations for modulating Lyn kinase activity and treating related disorders
US7776870B2 (en) 2005-08-22 2010-08-17 Melior Pharmaceuticals I, Inc. Methods for modulating Lyn kinase activity and treating related disorders
US11033548B2 (en) 2005-08-22 2021-06-15 Melior Pharmaceuticals I, Inc. Methods and formulations for modulating Lyn kinase activity and treating related disorders
US12070461B2 (en) 2005-08-22 2024-08-27 Melior Pharmaceuticals I, Inc. Methods and formulations for modulating Lyn kinase activity and treating related disorders
US8552184B2 (en) 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
US12011445B2 (en) 2010-05-28 2024-06-18 Melior Pharmaceuticals I, Inc. Prevention of pancreatic cell degeneration
US10786503B2 (en) 2017-04-10 2020-09-29 Melior Pharmaceuticals I, Inc. Treatment of adipocytes
US11534442B2 (en) 2017-04-10 2022-12-27 Melior Pharmaceuticals I, Inc. Treatment of adipocytes
US12064432B2 (en) 2017-04-10 2024-08-20 Melior Pharmaceuticals I, Inc. Treatment of adipocytes

Also Published As

Publication number Publication date
FI55503C (fi) 1979-08-10
NO136574C (no) 1977-09-28
JPS5422995B2 (fr) 1979-08-10
NL166470B (nl) 1981-03-16
DE2248741C3 (de) 1975-06-26
DE2264374A1 (de) 1973-05-24
LU66304A1 (fr) 1973-05-03
AU467600B2 (en) 1975-12-04
GB1377720A (en) 1974-12-18
SE397090B (sv) 1977-10-17
AR198798A1 (es) 1974-07-24
JPS4852780A (fr) 1973-07-24
AT321308B (de) 1975-03-25
DE2248741A1 (de) 1973-05-03
PL89852B1 (fr) 1976-12-31
IL40458A (en) 1976-05-31
ES407730A1 (es) 1976-01-16
IL48790A (en) 1976-05-31
DK131465C (fr) 1975-12-08
FR2157865A1 (fr) 1973-06-08
PH11594A (en) 1978-03-31
IE37043B1 (en) 1977-04-27
BE790125A (fr) 1973-04-16
AT320656B (de) 1975-02-25
NL166470C (nl) 1981-08-17
SE7505279L (sv) 1975-05-06
JPS5337870B2 (fr) 1978-10-12
FR2157865B1 (fr) 1975-10-31
NO136574B (fr) 1977-06-20
PL84634B1 (fr) 1976-04-30
DK131465B (da) 1975-07-21
YU255172A (en) 1980-03-15
PH10129A (en) 1976-09-02
DE2264374C3 (de) 1981-07-23
SU498908A3 (ru) 1976-01-05
YU35125B (en) 1980-09-25
IL40458A0 (en) 1972-11-28
EG11013A (en) 1976-11-30
IL48790A0 (en) 1976-03-31
DE2264657A1 (de) 1974-06-20
SE393376B (sv) 1977-05-09
ES436624A1 (es) 1977-02-01
CA980778A (en) 1975-12-30
YU99179A (en) 1981-08-31
ZA727362B (en) 1973-11-28
DE2264374B2 (de) 1980-08-07
DE2248741B2 (de) 1974-11-14
AU4722872A (en) 1974-04-04
CH549579A (fr) 1974-05-31
IE37043L (en) 1973-04-29
JPS53116386A (en) 1978-10-11
NL7213959A (fr) 1973-05-02
AR196263A1 (es) 1973-12-10
CH555832A (fr) 1974-11-15
YU36295B (en) 1982-06-18
FI55503B (fi) 1979-04-30
DE2264657C2 (de) 1982-09-16
SU505362A3 (ru) 1976-02-28

Similar Documents

Publication Publication Date Title
ES480542A1 (es) Metodo para producir derivados de imidazol.
GB1359563A (en) Pyrazolo-pyrimidines useful as xanthine oxidase inhibitors
GB1377308A (en) Pyrimidones
GB1429141A (en) 1-substituted pyrazol-5-ones their production and their medicinal use
GB1411583A (en) Aminophenyl-substituted alkyl-heterocyclic derivatives and processes for producing them
GB1456627A (en) Pyridobenzodiazepinones
GB1495665A (en) Pyrimidines
IL40329A (en) History of pyridine, their production and use as antimicrobial agents
GB1328935A (en) Substituted cycloalkyl lactamimides
GB1168391A (en) Substituted Uracils
GB1174349A (en) Novel 2-Anilinomethylimidazoline Derivatives and process for the preparation thereof
SE7415015L (sv) Sett att framstella nya 2-fenylhydrazino-tiazoliner eller -tiaziner
GB1445765A (en) Phenoxy-substituted malonic acid derivatives their prepration and pharmaceutical compositions containing them
GB1164555A (en) New Tropine Derivatives
GB1131164A (en) Novel halogen-substituted tetrahydroquinazoline derivatives, their preparation and compositions containing them
GB1500962A (en) Furo(2,3-d)pyrimidine derivatives
GB1353545A (en) S-triazine derivatives and their salts and process for producing them
GB1373276A (en) 2-aryl-amino-imidazoline-2 compounds
GB1316894A (en) Benzimidazole derivatives
GB1254270A (en) Benzoxazepine derivatives
GB1187071A (en) N-Amino-Substituted 4-Anilino-Pyridines
GB1173809A (en) N-Substituted Nor-Morphines
GB1242096A (en) Benzobenzofuranooxepine compounds and process for preparing the same
GB1409828A (en) Pharmaceuticals and process for their preparation
GB1504683A (en) Pharmaceutical compositions containing substituted pyrimido-quinoline derivatives

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PCNP Patent ceased through non-payment of renewal fee